nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.07.2012 | Kalzium in der kardialen Pathophysiologie

Pharmacology of myocardial calcium-handling

verfasst von: Julia Vogler, MD, Lars Eckardt, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2012

Einloggen, um Zugang zu erhalten

Summary

Disturbed myocardial calcium (Ca⁺) handling is one of the pathophysiologic hallmarks of cardiovascular diseases such as congestive heart failure, cardiac hypertrophy, and certain types of tachyarrhythmias. Pharmacologic treatment of these diseases thus focuses on restoring myocardial Ca²⁺ homeostasis by interacting with Ca²⁺-dependent signaling pathways. In this article, we review the currently used pharmacologic agents that are able to restore or maintain myocardial Ca²⁺ homeostasis and their mechanism of action as well as emerging new substances.

Vorheriger Artikel Calcium antagonists in myocardial ischemia/reperfusion—update 2012

Nächster Artikel Odontogene Infektionen – Teil I

Endoh M. Mechanism of action of Ca²⁺ sensitizers–update 2001. Cardiovasc Drugs Ther. 2001;15:397–403.PubMedCrossRef

Frishman WH, Saunders E. beta-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13:649–53.CrossRef

Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med. 2004;116:35–43.PubMedCrossRef

Chen X, Houser SR. Pharmacology of L-type and T-type calcium channels in the heart. In: Zipes D, Jalife J, editors. Cardiac electrophysiology—from cell to bedside. Philadelphia: Saunders Elsevier; 2009. p. 175–85.

Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999;99:1265–70.PubMedCrossRef

Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.PubMedCrossRef

Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.PubMedCrossRef

Hood WB, Dans A, Guyatt GH, Jaeschke R, McMurray J. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2001;3:CD002901.

Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol. 2002;40:323–38.PubMedCrossRef

10.

Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C. Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther. 2007;114:184–97.PubMedCrossRef

11.

Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13–29.PubMedCrossRef

12.

Wagner JA, Weisman HF, Levine JH, Snowman AM, Snyder SH. Differential effects of amiodarone and desethylamiodarone on calcium antagonist receptors. J Cardiovasc Pharmacol. 1990;15:501–7.PubMedCrossRef

13.

Nokin P, Clinet M, Schoenfeld P. Cardiac beta-adrenoceptor modulation by amiodarone. Biochem Pharmacol. 1983;32:2473–7.PubMedCrossRef

14.

Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009;120:636–44.CrossRef

15.

Woosley RL, Funck-Brentano C. Overview of the clinical pharmacology of antiarrhythmic drugs. Am J Cardiol. 1988;61:61A–9A.PubMedCrossRef

16.

Van Der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244–54.PubMedCrossRef

17.

Pott C, Dechering DG, Reinke F, Muszynski A, Zellerhoff S, Bittner A, et al. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. Europace. 2011;13:897–901.PubMedCrossRef

18.

Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, et al. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca²⁺ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol. 2010;48:293–301.PubMedCrossRef

19.

Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol. 2009;54:279–86.PubMedCrossRef

20.

Pott C, Steinritz D, Napp A, Bloch W, Schwinger RH, Brixius K. On the function of beta3-adrenoceptors in the human heart: signal transduction, inotropic effect and therapeutic prospects. Wien Med Wochenschr. 2006;156:451–8.PubMedCrossRef

Titel: Pharmacology of myocardial calcium-handling
verfasst von: Julia Vogler, MD
Lars Eckardt, MD
Publikationsdatum: 01.07.2012
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 13-14/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-012-0108-x

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13-14/2012

Arrhythmia-associated cardiac Ca2+ cycling proteins and gene mutations

Calcium antagonists in myocardial ischemia/reperfusion—update 2012

The physiology of cardiac calcium handling

Calcium handling and atrial fibrillation

Calcium handling in human heart failure—abnormalities and target for therapy

Odontogene Infektionen – Teil I